Overview

A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Rituximab